Showing results (221-230 of 321) with videos related to

Sort By:
Pageof 33
Arthritis and Rheumatism|December 1, 2007
Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled studyRobert G W Lambert, David Salonen, Proton Rahman, et al.
Annals of the Rheumatic Diseases|January 19, 2011
High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritisProton Rahman, Nicole M Roslin, Fawnda J Pellett, et al.
Annals of the Rheumatic Diseases|May 14, 2021
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb studyPhilip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, et al.
Plos One|August 15, 2014
Bone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitisYoung Bin Joo, So-Young Bang, Tae-Hwan Kim, et al.
RMD Open|July 31, 2021
Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 studyPhilip J Mease, Robert Landewé, Proton Rahman, et al.
Clinical Rheumatology|October 3, 2023
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatmentPhilip J Mease, Alice B Gottlieb, Alexis Ogdie, et al.
BMJ Open|September 1, 2017
Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registryProton Rahman, Michel Zummer, Louis Bessette, et al.
The Journal of Rheumatology|November 3, 2010
Genetic studies of ankylosing spondylitis in Koreans confirm associations with ERAP1 and 2p15 reported in white patientsSo-Young Bang, Tae-Hwan Kim, Bitnara Lee, et al.
Annals of the Rheumatic Diseases|May 10, 2015
Private rare deletions in SEC16A and MAMDC4 may represent novel pathogenic variants in familial axial spondyloarthritisDarren D O'Rielly, Mohammed Uddin, Dianne Codner, et al.
The New England Journal of Medicine|October 1, 2015
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic ArthritisPhilip J Mease, Iain B McInnes, Bruce Kirkham, et al.
Pageof 33